Revance Therapeutics Inc RVNC commenced a plan to exit the OPUL payments business, citing that significant costs and resources required to support OPUL no longer align with the company's capital allocation priorities. The exit and restructuring activities predominantly include a reduction in OPUL personnel headcount, the termination of OPUL research and development activities, and a reduction of outside services expenses related to OPUL. The company expects to record a restructuring charge of up to $7.0 million for such activities. Exiting OPUL payments business by the end of Q1 2024 expects to free up approximately $20 million a year for reinvestment in DAXXIFY aesthetics and therapeutic commercial launches. With current cash, cash equivalents, and short-term investments of $319.7 million as of June 30, 2023, and the additional $50 million in notes funded through Athyrium Capital in August 2023, the company is funded to breakeven and expects to be Adjusted EBITDA positive in 2025.